Osteogenesis imperfecta: Epidemiology and pathophysiology

被引:1
|
作者
Martin E. [1 ]
Shapiro J.R. [1 ]
机构
[1] Kennedy Krieger Intitute, Baltimore, MD 21205
关键词
Bone Mineral Density; Teriparatide; Osteogenesis Imperfecta; Pamidronate; Intravenous Pamidronate;
D O I
10.1007/s11914-007-0023-z
中图分类号
学科分类号
摘要
Osteogenesis imperfecta (OI) is the most common of the inherited connective tissue disorders that primarily affect bone. However, it is a systemic disorder, as evidenced by the occurrence of ocular complications, dentinogenesis imperfecta, hearing loss, joint laxity, restrictive pulmonary disease, and short stature. The OI classification initially included four phenotypes (I-IV) involving COL1A1 and COL1A2 mutations. Three new phenotypes have been added, of which one, type VII, is the result of mutations of the cartilage-associated protein (CRTAP) gene. Investigation of recessive forms of OI particularly reported among South African blacks have revealed mutations involving both the CRTAP gene and the leucine proline-enriched proteoglycan 1 (LEPRE1) gene, each involved in collagen proline-3 hydroxylation. Issues related to the treatment of OI with bisphosphonates involve patient selection, evaluation of the results of treatment, and the duration of treatment. Also, questions exist regarding the difference in treatment response between children and adults with OI. Other treatment options, such as recombinant human parathyroid hormone (1-34), Rank ligand inhibitors, and stem cell technology, are being evaluated or are of future investigative interest. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:91 / 97
页数:6
相关论文
共 50 条
  • [41] Personalized medicine in patients with Osteogenesis imperfecta
    Oliver Semler
    Heike Hoyer-Kuhn
    Joerg Doetsch
    Eckhard Schoenau
    Molecular and Cellular Pediatrics, 1 (Suppl 1)
  • [42] Osteogenesis Imperfecta: Current and Prospective Therapies
    Botor, Malwina
    Fus-Kujawa, Agnieszka
    Uroczynska, Marta
    Stepien, Karolina L.
    Galicka, Anna
    Gawron, Katarzyna
    Sieron, Aleksander L.
    BIOMOLECULES, 2021, 11 (10)
  • [43] Bisphosphonate therapy for severe osteogenesis imperfecta
    Glorieux, FH
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2000, 13 : 989 - 992
  • [44] Advances in the Classification and Treatment of Osteogenesis Imperfecta
    Thomas, Inas H.
    DiMeglio, Linda A.
    CURRENT OSTEOPOROSIS REPORTS, 2016, 14 (01) : 1 - 9
  • [45] Advances in the Orthopedic Management of Osteogenesis Imperfecta
    Laron, Dominique
    Pandya, Nirav K.
    ORTHOPEDIC CLINICS OF NORTH AMERICA, 2013, 44 (04) : 565 - +
  • [46] Treatment of children with Osteogenesis imperfecta in Estonia
    Maasalu, K
    Haviko, T
    Märtson, A
    ACTA PAEDIATRICA, 2003, 92 (04) : 452 - 455
  • [47] Therapy with pamidronate in children with osteogenesis imperfecta
    Marginean, Otilia
    Tamasanu, Raluca Corina
    Mang, Niculina
    Mozos, Ioana
    Brad, Giorgiana Flavia
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2507 - 2515
  • [48] Osteogenesis imperfecta: Practical treatment guidelines
    Antoniazzi F.
    Mottes M.
    Fraschini P.
    Brunelli P.C.
    Tatò L.
    Paediatric Drugs, 2000, 2 (6): : 465 - 488
  • [49] The Spine in Osteogenesis Imperfecta
    John P. Lubicky
    Spine Deformity, 2012, 1 (Suppl 1) : 124 - 132
  • [50] Osteogenesis imperfecta: a review
    Ablin, DS
    CANADIAN ASSOCIATION OF RADIOLOGISTS JOURNAL-JOURNAL DE L ASSOCIATION CANADIENNE DES RADIOLOGISTES, 1998, 49 (02): : 110 - 123